We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Mar 19, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX - Free Report) . The company’s robust worldwide commercial capabilities and best-in-class products, including its next-generation chemistry analyzer, Catalyst One, would be key growth drivers in the days to come. The stock carries a Zacks Rank #2 (Buy), at present.
Over the past six months, IDEXX has been outperforming its industry with respect to share price movement. The stock has gained 32.8% compared with 2.9% rise of the industry.
IDEXX exited the fourth quarter of 2020 with better-than-expected results. Solid organic-revenue growth is encouraging. The top line was driven by strong sales at the CAG and LPD businesses. The company witnessed sturdy gains in CAG Diagnostics recurring revenues, supported by sustained strong global trends in pet healthcare in the quarter under review. The company’s performance in major geographies is also encouraging.
Further, the company’s human health business, OPTI Medical Systems’ COVID-19 human Polymerase Chain Reaction (PCR) testing also contributed to the top line. The upbeat initial financial outlook for 2021 provided by the company also instills investor confidence in the stock. Margin expansions are encouraging.
Amid the pandemic-led restrictions, IDEXX witnessed a sequential improvement in CAG instrument placements during the fourth quarter. Further, the quality of CAG instrument placements remained high despite the constraint on overall placement levels. Globally, IDEXX placed 414 Catalysts at new and competitive accounts in North America and 1,092 new and competitive placements in international markets.
Global Reference Lab revenues increased 18.9% organically, reflecting nearly 20% organic growth in the United States and mid-to-high teens organic gains in international markets. Gains in Reference lab revenues continue to be driven by high same-store volume growth along with strong gains across testing categories.
Nonetheless, the pandemic has limited the new CAG instrument placement levels, which is worrying. Other issues like foreign exchange fluctuations and impact of third-party distribution persist.
Meanwhile, the majority of IDEXX’s consolidated revenues is derived from the sale of products in international markets. Thus, the strengthening of the U.S. dollar exchange rate, relative to other currencies, left a negative impact on revenues derived in currencies other than the U.S. dollar as well as on profits drawn from products manufactured in the United States and sold internationally.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , Hologic, Inc. (HOLX - Free Report) and Abbott Laboratories (ABT - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 15.4%. The company presently carries a Zacks Rank #2 (Buy).
Abbott’s long-term earnings growth rate is estimated at 14.1%. The company presently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
On Mar 19, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX - Free Report) . The company’s robust worldwide commercial capabilities and best-in-class products, including its next-generation chemistry analyzer, Catalyst One, would be key growth drivers in the days to come. The stock carries a Zacks Rank #2 (Buy), at present.
Over the past six months, IDEXX has been outperforming its industry with respect to share price movement. The stock has gained 32.8% compared with 2.9% rise of the industry.
IDEXX exited the fourth quarter of 2020 with better-than-expected results. Solid organic-revenue growth is encouraging. The top line was driven by strong sales at the CAG and LPD businesses. The company witnessed sturdy gains in CAG Diagnostics recurring revenues, supported by sustained strong global trends in pet healthcare in the quarter under review. The company’s performance in major geographies is also encouraging.
Further, the company’s human health business, OPTI Medical Systems’ COVID-19 human Polymerase Chain Reaction (PCR) testing also contributed to the top line. The upbeat initial financial outlook for 2021 provided by the company also instills investor confidence in the stock. Margin expansions are encouraging.
IDEXX Laboratories, Inc. Price
IDEXX Laboratories, Inc. price | IDEXX Laboratories, Inc. Quote
Amid the pandemic-led restrictions, IDEXX witnessed a sequential improvement in CAG instrument placements during the fourth quarter. Further, the quality of CAG instrument placements remained high despite the constraint on overall placement levels. Globally, IDEXX placed 414 Catalysts at new and competitive accounts in North America and 1,092 new and competitive placements in international markets.
Global Reference Lab revenues increased 18.9% organically, reflecting nearly 20% organic growth in the United States and mid-to-high teens organic gains in international markets. Gains in Reference lab revenues continue to be driven by high same-store volume growth along with strong gains across testing categories.
Nonetheless, the pandemic has limited the new CAG instrument placement levels, which is worrying. Other issues like foreign exchange fluctuations and impact of third-party distribution persist.
Meanwhile, the majority of IDEXX’s consolidated revenues is derived from the sale of products in international markets. Thus, the strengthening of the U.S. dollar exchange rate, relative to other currencies, left a negative impact on revenues derived in currencies other than the U.S. dollar as well as on profits drawn from products manufactured in the United States and sold internationally.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , Hologic, Inc. (HOLX - Free Report) and Abbott Laboratories (ABT - Free Report) .
Envista’s long-term earnings growth rate is estimated at 24%.It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic’s long-term earnings growth rate is estimated at 15.4%. The company presently carries a Zacks Rank #2 (Buy).
Abbott’s long-term earnings growth rate is estimated at 14.1%. The company presently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>